PHILADELPHIA--(BUSINESS WIRE)--June 12, 2006--Hemispherx Biopharma, Inc. (AMEX: HEB - News) announced that the Company had completed final design of a well-controlled, Ampligen® vs. placebo, immunopotentiation trial of seasonal influenza vaccinations. The design follows closely newly published FDA guidelines for determining potential efficacy. The clinical study seeks to extend the findings from the preclinical models, including primates, being conducted in collaboration with the Japanese National Institute for Infectious Diseases, to determine the extent to which Ampligen® may increase the effectiveness of vaccines and thereby broaden the availability of flu vaccine doses to treat more at-risk groups, such as senior citizens.
